Compare GSK plc (GSK) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Solaredge Technologies Inc — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Solaredge Technologies Inc trades at $32.08 (market cap $2.00B). The key difference: GSK plc is far larger — about 45.9× Solaredge Technologies Inc's market cap, and GSK plc pays a 3.9% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Solaredge Technologies Inc for 34 Days on average.
| GSK | SEDG | |
|---|---|---|
Market Cap | $91.88B | $2.00B |
Volume | 7,730,529 | 2,739,860 |
Sector | Health | Energy |
52-Week High | $61.18 | $78.51 |
52-Week Low | $43.24 | $28.47 |
Typical Hold Time | 93 Days | 34 Days |
Enterprise Value | $111.88B | $1.86B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
SolarEdge Technologies (SEDG) trades at $32.21, down 2.86% on the day, amid a bearish technical signal and mixed earnings performance. The company reported a net loss of $405.45M in 2025, with negative profit margins, though revenue grew to $1.18B. Recent news highlights legal investigations and volatility driven by solar sector pressures and new AI data center initiatives announced in September 2026.
The outlook remains cautious due to persistent losses and high debt, but analyst consensus suggests moderate upside to a $37.75 price target. Key risks include ongoing legal scrutiny, competitive pressures, and reliance on solar market recovery. Investment appeal hinges on execution of growth targets and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
